Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BioCorRx to Present at the 2017 Marcum Microcap Conference
Published:Wednesday, June 7th 2017, 7:23 am EDT
Updated:Wednesday, June 7th 2017, 8:23 am EDT
ANAHEIM, CA / ACCESSWIRE / June 7, 2017 / BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that it will be presenting at the 2017 Marcum MicroCap Conference on Thursday, June 15th at 3:30 PM EST. Brady Granier, President, CEO and Director, and Lourdes Felix, CFO and COO of BioCorRx, will be presenting and meeting with investors.
The Marcum MicroCap Conference (www.marcummicrocap.com) is a nationally recognized forum for publicly traded companies with less than $500 million in market capitalization to network with fund managers and high net worth investors who focus on small cap equities. More than 2000 investors and other participants from every segment of the microcap marketplace attend each year, including venture and lower middle-market private equity investors, institutional investors, directors, investment bankers, and buy- and sell-side analysts, as well as senior executive teams from presenting companies and service providers to the microcap marketplace.
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a proprietary counseling program (plus peer support program) specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The Company plans to seek FDA approval for BICX101 and/or its naltrexone implant product(s). For more information on BICX, visit www.BioCorRx.com.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
SOURCE: BioCorRx Inc.
BioCorRx Inc.: BioCorRx Partners with the Virtual Reality Medical Center and Physicians at Scripps Memorial Hospital for Naltrexone Implant Study, Grant Assistance and Strategic Partnershi
ANAHEIM, CA / ACCESSWIRE / June 1, 2017 / BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that it has partnered with the Virtual Reality Medical Center (VRMC), led by Drs. Mark and Brenda Wiederhold, as well as Dr. Joseph Shurman, co-director of the Pain and Palliative Care Committee at Scripps Memorial Hospital in La Jolla, California to conduct a study on the BioCorRx Recovery Program and the Company's long lasting naltrexone implant.
VRMC plans to conduct studies at its office in the Scripps Memorial Hospital Campus where they have access to the expertise and experience of the Scripps physicians and community. Drs. Mark and Brenda Wiederhold will be working closely with Dr. Joseph Shurman. VRMC has extensive experience in establishing Institutional Review Boards (IRB) and preparation of Investigational New Drug (IND) applications with the FDA, which it will bring to its partnership with BioCorRx. Additionally, VRMC has over 30 years of experience in applying for and securing government grants and contracts. VRMC plans to seek additional grant funding from the National Institutes of Health to support further clinical research related to BioCorRx's naltrexone implant and recovery program.
VRMC brings over 20 years of experience in the use of advanced technologies, such as Virtual Reality (VR), tele-behavioral health and real-time biosensor data analysis using artificial intelligence. VRMC has been effectively treating patients in its clinics and providing comprehensive VR training and treatment programs to the U.S. Government, the Department of Defense, the Veterans Administration, NATO and European Commission. VRMC is a leader in providing the tools for patient assessment and treatment both in the clinic and is actively transitioning healthcare to both mobile devices and the home setting.
Brady Granier, President, CEO and Director, stated, "We are honored to be working with such highly respected doctors at Scripps Memorial Hospital, a premier medical facility. They will be helping us set up and conduct the study on our naltrexone implant and recovery program for alcohol and opioid addictions with the goal of validating the program's effectiveness to the broader medical community. We believe that by conducting this study, we will gain even more third-party support for our program which has already helped countless individuals over the years. Not only can this study be helpful for educating practitioners, but it may also help lay the foundation for broader national awareness and reimbursement. They will also be assisting us with grant submissions, which could support future research on our naltrexone products. Dr. Shurman is also a valuable addition to our team. Not only is he going to assist Drs. Mark and Brenda Wiederhold with the studies, but he will provide key introductions to potential strategic partners and healthcare professionals in the pain management and addiction fields."
Dr. Brenda K Wiederhold, President of the Virtual Reality Medical Center & Medical Staff, Scripps Memorial Hospital, stated, "We are pleased to work with BioCorRx in developing strategies to combat an issue that has become a national priority."
Dr. Mark D. Wiederhold, M.D., Ph.D, CEO of VRMC, commented "The ability to strategically combine both pharmacological and technical interventions is clearly the future to successfully addressing the crisis in opioid addiction."
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a proprietary counseling program (plus peer support program) specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The Company plans to seek FDA approval for BICX101 and/or its naltrexone implant product(s). For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
SOURCE: BioCorRx Inc.
BioCorRx to Host Grand Opening Ribbon Cutting,
Support Drug Free Anaheim Initiative in the City of Anaheim
ANAHEIM, Calif., May 30, 2017 — BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced it will host its grand opening ribbon cutting on Monday, June 5, at the Company’s new corporate office in Anaheim, California. As previously announced this year, the Company is offering treatment services as part of the city’s Drug Free Anaheim initiative. Anaheim Mayor Tom Tait will be in attendance at the event.
BioCorRx is offering its BioCorRx® Recovery Program to Anaheim residents suffering from alcohol and opioid addiction as part of Drug Free Anaheim, an initiative launched earlier this year that encourages those suffering from substance use disorder to seek assistance. Under Drug Free Anaheim, those struggling with addiction can ask for help from the Anaheim Police Department and its nonprofit partner without fear of prosecution. More on the program, including full details and eligibility information, can be found at Anaheim.net/drugfree.
The BioCorRx® Recovery Program includes a naltrexone implant produced per patient use, combined with a structured, proprietary counseling program and peer support for a year. These specifically formulated, biodegradable pellets are typically inserted beneath the skin in the lower abdominal area. Naltrexone is a non-addictive opioid antagonist used for the treatment of alcohol and opioid dependence. It can reduce or eliminate cravings for alcohol and opioids as well as block dangerous effects of opioid use such as overdose, as commonly seen in heroin use. The implant provides a window of opportunity for one to get through the counseling and support portion of the program which is important for long term sobriety
“We know we cannot arrest our way out of drug problems facing our community,” Mayor Tom Tait said. “There is a place for law enforcement, and a place for compassion. We need to look at alternatives to the criminal justice system as well as advances in treatment. We welcome BioCorRx to Anaheim and thank the Company for its interest in helping those struggling with addiction.”
Brady Granier, President, CEO and Director stated, “We moved to Anaheim less than a year ago and appreciate the support that we have received thus far from the city. We believe our treatment program will help local residents who want help by taking part in this wonderful city initiative. We hope that this collaboration shines a light on solutions available today across the U.S. that really work to combat this crisis. We also want to thank the Anaheim Chamber of Commerce for its assistance with this event.”
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a proprietary counseling program (plus peer support program) specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The Company plans to seek FDA approval for BICX101 and/or its naltrexone implant product(s). For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
Big day ahead of us
NSAV Announces FINRA Approval and Effectiveness of Stock Dividend
Font size: A | A | A
9:25 AM ET 5/25/17 | Marketwired
CRESCO, PA--(Marketwired - May 25, 2017) - Net Savings Link, Inc. (OTC: NSAV), announced today that FINRA has approved and made effective the Company's previously announced 10% common stock dividend, which has a record date of June 1, 2017. The public is advised that the final day to purchase NSAV shares in order to receive the dividend is Friday, May 26, 2017.
http://otce.finra.org/DLDividendsDistributionsSplit
NSAV, a cannabis technology and advisory company, previously announced the dividend on April 24, 2016 and disclosed the event in an SEC Form 8-K on the same date.
James Tilton, president of NSAV, stated, "I am extremely pleased that the FINRA approval of the Company's dividend came so quickly and well before the record date. This will certainly benefit all of our loyal NSAV shareholders."
NSAV's vision is the establishment of a fully integrated technology company that provides turnkey technological solutions to the legal medical cannabis industry, as well as other areas of the medical industry. Over time, the Company plans to provide a wide range of services such as software solutions, e-commerce, advisory services, financial services, patents and trademarks and information technology.
For further information please contact NSAV at 1 (570-595-2432) or jamestilton@netsavingslinkinc.com.
The NSAV corporate website can be accessed at http://netsavlink.com
The NSAV Twitter account can be accessed at https://twitter.com/NSAV_MJTechCo
The NSAV Facebook account can be accessed at https://www.facebook.com/Net-Savings-Link-Inc-768628693317257/
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that, all forward-looking statements involve risks and uncertainties, including without limitation, the ability of Net Savings Link, Inc. to accomplish its stated plan of business. Net Savings Link, Inc. believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward- looking statements included herein, the inclusion of such information should not be regarded as a representation by Net Savings Link, Inc. or any other person.
NSAV 1 (570-595-2432) jamestilton@netsavingslinkinc.com
just for the FDA to agree on setting up a meeting means BIOCORRX have something in its product that is worth the FDA time ...
Very excited !!!!
BioCorRx Granted Pre-IND Meeting with FDA for BICX101
Published:Thursday, May 25th 2017, 7:26 am EDT
Updated:Thursday, May 25th 2017, 8:26 am EDT
ANAHEIM, CA / ACCESSWIRE / May 25, 2017 / BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that the U.S. Food & Drug Administration (FDA) has granted a pre-IND meeting to the Company and it is scheduled to take place on Tuesday, September 19, 2017 in order to review the development plan to market BICX101, an injectable, sustained release naltrexone, for the treatment of opioid addiction and alcohol use disorders.
At the pre-IND meeting, BioCorRx plans to seek acceptance from the FDA on its proposal to file a New Drug Application (NDA) under Section 505(b)(2) for approval of BICX101, based on the FDA’s previous determination of the safety and effectiveness of naltrexone for the treatment of opioid addiction and alcohol use disorders.
Brady Granier, President, CEO and Director, stated, “We are appreciative of the FDA’s response and look forward to meeting with them to present our plan for BICX101. Between now and the meeting date, we will continue to conduct more preclinical studies on BICX101 at Covance in order to collect additional data which will go into our briefing document to the FDA and IND filing. We continue to be excited about the potential for BICX101 to be utilized for multiple substance use disorder indications in the future.”
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a proprietary counseling program (plus peer support program) specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The Company plans to seek FDA approval for BICX101 and/or its naltrexone implant product(s). For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
SOURCE: BioCorRx Inc.
ReleaseID: 464148
Information contained on this page is provided by an independent third-party content provider. Frankly and this Station make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com
Biocorrx Inc (BICX) is a Top Mover
May 23, 2017 Nelson Research Staff
Volume is the number of shares traded over a specified time period. Every seller has a buyer, and every transaction is added to the total count of the volume. When a buyer and a seller agree on a transaction at a specific price, one transaction has occured. If fifty transactions occur in a trading day, the volume for the day is fifty. Volume can be used to measure the relative worth of a market move. When the markets make a big price movement, the strength of that movement is derived from the volume over that period. The higher the volume, the more significant the move. Volume give clues about the best entry and exit points. Biocorrx Inc (BICX) had a volume of 55914.
Volume is an important measure of strength for traders and technical analysts because volume is the number of contracts traded. The market needs to produce a buyer and a seller for any trade to occur. The market price is when buyers and sellers meet. When buyers and sellers become very active at a certain price, this means that there is high volume.
A 52-week high/low is the highest and lowest share price that a stock has traded at during the previous year. Investors and traders consider the 52-week high or low as a crucial factor in determining a given stock’s current value while also predicting future price movements.
When an equity trades within its 52-week price range (the range that exists between the 52-week low and the 52-week high), investors usually show more interest as the price nears either the high or the low. One of the more popular strategies used by traders is to buy when the price eclipses its 52-week high or to sell when the price drops below its 52-week low. The rationale involved with this strategy says that if the price breaks out either above or below the 52-week range, there is momentum enough to continue the price fluctuation in a positive direction.
Biocorrx Inc (BICX)’s high over the last year was $0.34 while its low was $0.01.
Biocorrx Inc (BICX)’s 52-Week Percent Change, the difference between the current price and the settlement price from 1 year ago, is +646.27%.
A “pivot point” is a technical analysis indicator used to glean the overall trend of the market over differing time periods. The pivot point itself is simply the average of the high, low and closing prices from the previous day’s trading. On the following day, any trading above the pivot point indicates ongoing bullish trends, while trading below the pivot point indicates a bearish trend.
Pivot point analysis is used in alongside calculating support and resistance levels, much like trend line analysis. In pivot point analysis, the first support and resistance levels are found by utilizing the width of the trading range between the pivot point and either the high or low prices of the previous trading day. Secondary support and resistance levels are found using the full width between the high and low prices of the previous trading day.
Pivot points are oft-used indicators for trading futures, commodities, and stocks. They are static, remaining at the same price level throughout the day. Five pivot point levels are generated by using data from the previous day’s trading range. These are composed of a pivot point and two higher pivot point resistances called R1 and R2 and also two lower pivot point supports called as S1 and S2. Biocorrx Inc (BICX)’s Pivot Point is 0.1476. Its 1st Resistance Point is 0.1528 and its 2nd Resistance Point is 0.1553. The 1st Support Point is 0.1451 while its 2nd Support Point is 0.1399. Biocorrx Inc (BICX)’s TrendSpotter Opinion, the signal from Trendspotter, a Barchart trend analysis system that uses wave theory, market momentum & volatility in an attempt to find a general trend, is Sell. Barchart Opinions show investors what a variety of popular trading systems are suggesting.
These Opinions take up to 2 years’ worth of historical data and runs the prices through thirteen technical indicators. After each calculation, a buy, sell or hold value for each study is assigned, depending on where the price is in reference to the interpretation of the study. Today’s opinion, the overall signal based on where the price lies in reference to the common interpretation of all 13 studies, for Biocorrx Inc (BICX) is 8% Sell.
CNS Cluster Addiction Drug Development Pipeline Review 2017 - Research and Markets
May 23, 2017 07:21 AM Eastern Daylight Time
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "CNS Cluster Addiction Drug Development Pipeline Review, 2017" report to their offering.
“CNS Cluster Addiction Drug Development Pipeline Review, 2017”
Tweet this
This report provides an overview of the CNS Clusters pipeline landscape. The report provides comprehensive information on the therapeutics under development, and key players involved in therapeutic development for Alcohol Addiction, Drug Addiction, Nicotine Addiction, Opium (Opioid) Addiction and features dormant and discontinued projects.
Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression, restlessness, inability to control drinking and violent behavior. There are a total of 38 products in development for this indication, by 29 companies and five academic institutions. Key companies operating in this pipeline space include Abbvie, Astraea Therapeutics, Lochola Research and SK Biopharmaceuticals.
Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. There are a total of 67 products in development for this indication, by 38 companies and 16 academic institutions. Key companies operating in this pipeline space include Astraea Therapeutics, Addex therapeutics, The University of Kansas, Embera NeuroTherapeutics, InterveXion Therapeutics, Omeros, Opiant Pharmaceuticals and Orexigen Therapeutics.
Nicotine addiction also called tobacco dependence is an addiction to tobacco products caused by the drug nicotine. There are a total of 19 products in development for this indication, by 13 companies and 5 academic institutions. The majority of companies are developing single pipeline program in this space, while Omeros are developing two.
Finally, opioid addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). There are a total of 33 products in development for this indication, by 23 companies and three academic institutions. Key companies operating in this pipeline space include Indivior, INSYS Therapeutics, Omeros, Pfizer and Zynerba Pharmaceuticals.
There is a substantial degree of overlap between these indications in terms of the types of molecular target which are being studied. The mu and kappa-opioid receptors are the dominant molecular target across alcohol, drug and opioid addiction, and other neurotransmitter receptors such as the cannabinoid and dopamine receptors are common molecular targets across the three. In contrast, while such neurotransmitter receptors are present in the nicotine addiction pipeline, the opioid receptors are not, and the dominant molecular target is the orexin receptor type 1.
Scope
- Which companies are the most active within the pipeline for addiction therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of addiction therapeutics?
Key Topics Covered:
1. Report Guidance
2. Executive Summary
3. Introduction
4. CNS Cluster Addiction Report Coverage
5. Therapeutics Development
6. Therapeutics Assessment
7. Companies Involved in Therapeutics Development
8. Dormant Projects
9. Discontinued Products
10. Product Development Milestones
11. Appendix
Companies Featured
• Companies Mentioned
• AbbVie Inc
• Alkermes Plc
• Aoxing Pharmaceutical Company Inc
• Aphios Corp
• Aquilus Pharmaceuticals Inc
• Astraea Therapeutics LLC
• BioCorRx Inc
• BioDelivery Sciences International Inc
• Bionex Pharmaceuticals LLC
• Bioprojet SCR
• Euthymics Bioscience Inc
• F. Hoffmann-La Roche Ltd
• Foresee Pharmaceuticals LLC
• H. Lundbeck A/S
• Immunovaccine Inc
• Indivior Plc
• InterveXion Therapeutics LLC
• Intra-Cellular Therapies Inc
• Kinnov Therapeutics SAS
• Kyorin Pharmaceutical Co Ltd
• Kyowa Hakko Kirin Co Ltd
• Lohocla Research Corp
• MedRev Pharma
• Orexo AB
• P2D Bioscience
• Pfizer Inc
• Relmada Therapeutics Inc
• SK Biopharmaceuticals Co Ltd
• Saniona AB
• Savant HWP Inc
• Stada Arzneimittel AG
• Teva Pharmaceutical Industries Ltd
• Titan Pharmaceuticals Inc
• Tonix Pharmaceuticals Holding Corp
• Zynerba Pharmaceuticals Inc
For more information about this report visit http://www.researchandmarkets.com/research/63w8fp/cns_cluster
Contacts
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Discovery, Addiction Disorders Drugs
IMO !! Will start climbing again very soon
BioCorRx Provides Business Update for the First Quarter of 2017
ANAHEIM, CA, May 15, 2017 -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the first quarter ended March 31, 2017.
Brady Granier, President, CEO and Director, stated, “We have had a very productive first quarter of 2017. Our preclinical studies of BICX101, a sustained release, injectable naltrexone for the treatment of opioid and alcohol use disorders, showed positive preliminary data as announced previously. We also formally requested a pre-IND meeting with the U.S. Food & Drug Administration (FDA) and we continue to wait for official communication from the FDA on a meeting date. In the meantime, we are conducting more preclinical studies on BICX101 in order to compile more data points. This may allow us to fine tune our lead formulas with the goal of achieving maximum efficiency and results while we await the FDA meeting.”
“Turning to our recovery program, we continue to sign on more providers, and currently have over 15 providers offering our program nationwide. In February, we announced that we will assist the city of Anaheim, California, in treating residents with opioid and alcohol addiction. BioCorRx will offer its BioCorRx® Recovery Program to residents of Anaheim suffering from alcohol and opioid addiction as an expansion of the Drug Free Anaheim Program discussed in the mayor’s February 2017 State of the City address aimed at encouraging those dependent on substances to seek assistance. We are confident in the success of our non-addictive medication-assisted-treatment program, which combines peer support and counseling modules with a naltrexone implant. The effectiveness of our program has been demonstrated time and again over the last several years, with better compliance than traditional alternatives and unprecedented results. We believe that with the success of our program, we will be able to continue to expand into other counties and cities across the U.S.”
“Last month we announced that we entered into an agreement with DynamiCare Health, Inc. to develop a co-branded mobile application to support patients engaged in counseling for the treatment of alcoholism or opioid addiction and receiving long-term naltrexone treatment. The mobile application, DynamiCare Rewards™ with BioCorRx CBT, is being designed to offer patients a self-guided, interactive version of BioCorRx’s proprietary, naltrexone specific, Cognitive Behavioral Therapy (CBT) program. We look forward to the launch of the mobile application later this summer as development continues as planned.”
Lourdes Felix, CFO, COO and Director, commented, “In March, we announced that we completed an equity financing of $940,000 with accredited investors, and Alpine Creek Capital Partners invested an additional $1.7 million. This financing strengthens our balance sheet, while allowing us to continue to execute on our business plan, including completion of a few rounds of preclinical studies of BICX101 and accelerating sales and marketing activities related to our BioCorRx Recovery Program. This quarter included a significant non-cash expense related to the convertible debt and warrants that was particularly high due to the increase in the Company’s share price. Nevertheless, revenues increased sequentially from the fourth quarter of 2016 and we anticipate continued sequential growth throughout the balance of this year.”
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a proprietary counseling program (plus peer support program) specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The company plans to seek FDA approval for BICX101 and/or its naltrexone implant product(s). For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
BICX@crescendo-ir.com
212-671-1020 x304
Some buying starting to happen again !
North American Cannabis Holdings CEO Steven Rash Interviewed By Uptick Newswire
Source: InvestorsHub NewsWire
Dallas, Tx – May 5, 2017 North American Cannabis Holdings, Inc. (USOTC: USMJ) CEO Steven Rash was interviewed by Uptick Newswire. The interview includes details on the Company’s over $500,000 in annual revenue and recent product introductions. CEO Steven Rash also discusses the benefits of CBD and the Company’s marketing programs. Uptick Newswire Correspondent Everett Jolly highlights that USMJ is one of the few cannabis sector companies that actual has revenue.
To hear the interview:
CEO STEVEN RASH ON UPTICK NEWSWIRE WITH EVERTT JOLLY
Other companies featured recently on Uptick Newswire include BioCorRx Inc. (OTCQB: BICX), Marijuana Company of America (OTC Pink: MCOA), and Player’s Network, Inc. (OTCQB: PNTV)
Mentioned In the fox and friends video that some insurance companies are starting to pay for the implant :)
http://video.foxnews.com/v/5420217492001/?playlist_id=930909787001#sp=show-clips
Will try to email company regarding that point ! Great point though
Was expecting higher PPS along with the high volume !!?
Any new informations were shared to public in the fox and friends interview ?
Fox and friends interview link ?
Relative Strength Under the Microscope:Biocorrx Inc (BICX)
?May 2, 2017 ?Nelson Research Staff
Relative strength is a momentum-investing technique that compares the performance of an asset to the overall market. Using specific calculations, traders and investors can target the healthiest performers as compared to the market, creating investment recommendations. Relative strength says that a stock whose price has been rising will continue on that trend. Investors using relative strength always have entry and exit strategies. Traders and investors using this technique try to buy securities that are showing signs of strength and then selling them as soon as they begin to appear weak. Relative strength can also be applied to more complex strategies. Investors use relative strength identify top performers within a group of potential investments, comparing the performance of each security directly to another security or to a specific benchmark index, such as the S&P 500. Biocorrx Inc (BICX)’s 9-Day Relative Strength is 46.95% and its 14-Day Relative Strength is 51.42%. Taking a longer view back, its 20-Day Relative Strength is 54.05% and its 50-Day Relative Strength is 54.05% and, finally, its 100-Day Relative Strength is 57.86%.
The Open is the start of trading on a securities exchange. The open indicates the start of an official business day for an exchange, meaning that transactions may begin for the day.
The different exchanges have different opening times. Biocorrx Inc (BICX) opened at $0.2. Its high for the day was $0.2049, its low was $0.18 and last trade price was $0.195.
Standard Deviation is a measure of the current average variability of return. A move of (plus or minus) 1 std deviation means a 33% odds for a major price move, whereas a move of (plus or minus) 3 std deviations means a 1% odds for a major price move. Biocorrx Inc (BICX)’s Standard Deviation is -0.54.
Weighted Alpha is a measure of how much a stock has risen or fallen over a one-year period with a higher weighting for recent price activity. Biocorrx Inc (BICX)’s Weighted Alpha is -5.80.
Biocorrx Inc (BICX)’s TrendSpotter Opinion, the signal from Trendspotter, a Barchart trend analysis system that uses wave theory, market momentum & volatility in an attempt to find a general trend, is Buy.
Barchart Opinions show investors what a variety of popular trading systems are suggesting. These Opinions take up to 2 years’ worth of historical data and runs the prices through thirteen technical indicators.
After each calculation, a buy, sell or hold value for each study is assigned, depending on where the price is in reference to the interpretation of the study. Today’s opinion, the overall signal based on where the price lies in reference to the common interpretation of all 13 studies, for Biocorrx Inc (BICX) is 16% Buy.
Relative Strength is part of technical analysis. Technical analysis is a trading tool used to judge securities as well as attempt to forecast their future moves by analyzing trading activity statistics like volume and price fluctuations.
Where fundamental analysts attempt to evaluate the intrinsic value of a security, technical analytics observe charts of price movements and forecast future price movements through various analytical tools to evaluate a security’s strength or weakness.
Technical analysts believe in the idea that price changes of a security and past trading activity are better indicators of that given security’s future price movements than simply the intrinsic value of said security. Technical analysis was created out of simple concepts learned from Dow Theory, the theory of trading market movements that originated from the early writings of Charles Dow.
The two basic assumptions of Dow Theory say analysis are: 1.) market price discounts all the factors that could influence a security’s price and: 2.) market price movements are not simply random but move in an identifiable pattern and that repeat over time.
The first assumption, that price discounts everything, means the market price of a commodity at any given point in time perfectly reflects all available information, and re represents the security’s true fair value. It is based on the idea the market price always reflects the sum total knowledge of the market.
The second basic assumption, the notion that price changes are not just random, leads to the belief that both short term and long term market trends can be identified, allowing traders to profit from investing when following the existing trend.
Technical analysis is used in order to forecast the price movement of all tradable instruments that are subject to the forces of supply and demand, including currency pairs, bonds, stocks, and futures.
Technical analysis can be viewed simply as the study of supply and demand as reflected in market price movements of securities. It is usually applied to price changes, though analysts may also track numbers other than price, such as open interest figures or trading volume.
Many technical indicators have been developed by analysts over the years in an attempt to forecast future price movements accurately. Some indicators are focused on determining the how strong a trend is and also the possibility of its continuation while other indicators focus on identifying current market trends, including resistance areas and support.
Commonly used technical indicators include moving averages, trendlines, and momentum indicators like the moving average convergence divergence (MACD) indicator.
Technical analysts apply these indicators to charts of differing timeframes.
Short-term traders may use charts covering one-minute timeframes to hourly or even four-hour timeframes, and traders analyzing more long-term price movements look over daily, weekly or monthly charts.
Stock Spotter: Review on Technical Levels for BioCorRx Inc (BICX)
?May 2, 2017 ?Standard Staff Writer
BioCorRx Inc (BICX) has a current 14 day Williams %R reading of -61.11. Levels can range from 0 to -100. A Williams %R that falls between -80 to -100 is typically viewed as being in strong oversold territory. A value between 0 to -20 would represent a strong overbought condition. As a momentum indicator, the Williams R% has the ability to be used with other technicals to help define a specific trend.
BioCorRx Inc (BICX) presently has a 14-day Commodity Channel Index (CCI) of -90.35. Typically, the CCI oscillates above and below a zero line. Normal oscillations tend to stay in the range of -100 to +100. A CCI reading of +100 may represent overbought conditions, while readings near -100 may indicate oversold territory. Although the CCI indicator was developed for commodities, it has become a popular tool for equity evaluation as well. Checking on another technical indicator, the 14-day RSI is currently sitting at 52.18, the 7-day rests at 45.28, and the 3-day is presently at 36.68. The Relative Strength Index (RSI) is a highly popular technical indicator. The RSI is computed base on the speed and direction of a stock’s price movement. The RSI is considered to be an internal strength indicator, not to be confused with relative strength which is compared to other stocks and indices. The RSI value will always move between 0 and 100. One of the most popular time frames using RSI is the 14-day.
Moving average indicators are commonly tracked by technical stock analysts. Many traders will use a combination of moving averages with multiple time periods to help spot stock trend direction. One of the more popular combinations is to use the 50-day and 200-day moving averages. Investors may use the 200-day MA to help smooth out the data a get a clearer long-term picture. They may look to the 50-day or 20-day to get a better grasp of what is going on with the stock in the near-term. Presently, the 200-day moving average is at 0.07, and the 50-day is 0.15. The 14-day ADX for BioCorRx Inc (BICX) is standing at 30.01. Many chart analysts believe that an ADX reading over 25 would suggest a strong trend. A reading under 20 would suggest no trend, and a reading from 20-25 would suggest that there is no clear trend signal.
Get ready for the 0.30+ again in the next few days !!! May be higher :)
BioCorRx Collaborating with DynamiCare Health to Develop Mobile Application for Patients with Opioid and Alcohol Addiction
Anaheim, CA -- (ReleaseWire) -- 04/24/2017 --BioCorRx Inc. (OTCMKTS:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance use disorders, today announced it entered into an agreement with DynamiCare Health™, Inc. to develop a co-branded mobile application to support patients engaged in counseling for the treatment of alcoholism or opioid addiction and receiving long-term naltrexone treatment. DynamiCare Health is focused on building evidence-based tools that motivate people to live healthy lives.
The mobile application, DynamiCare Rewards™ with BioCorRx CBT, is being designed to offer patients a self-guided, interactive version of BioCorRx's proprietary, naltrexone specific, Cognitive Behavioral Therapy (CBT) program. The CBT program, in its current form, has been in use since 2015 by addiction counselors across the country as part of the company's comprehensive BioCorRx® Recovery Program. The platform will enable counselors to remotely monitor the progress of their patients as they complete the program modules. The BioCorRx program consists of 35 modules developed by addiction experts with years of experience counseling individuals receiving long term naltrexone therapy. DynamiCare Health will service the backend data provided by BioCorRx and provide a rewards system and reminder system to keep patients engaged in counseling.
Brady Granier, President, CEO and Director stated, "The agreement with DynamiCare Health marks an important step to advance our addiction recovery program virtually anywhere. We are proud of the results that independent treatment providers and their patients have been experiencing with our naltrexone specific, medication assisted treatment (MAT) program over the last few years. We look forward to collaborating with the founders of DynamiCare Health, David R. Gastfriend, MD and Eric Gastfriend, MBA, who bring extensive experience in the addiction market and mobile technologies, respectively. With this new technology platform, we believe that we can elevate our program to a new level to better serve our domestic partners and their patients, while creating potential new opportunities abroad. We look forward to seeing our counseling modules become tangible, interactive, and engaging via a mobile application. The development has already begun and we hope to receive the first version for testing this Summer."
Eric Gastfriend, co-founder of DynamiCare Health, commented, "We look forward to working closely with BioCorRx to develop a first-in-kind mobile application intended to support substance abuse treatment, creating a scalable tool that can improve outcomes and effectively measure results. We believe this revolutionary telemedicine drug recovery program has the potential to broadly transform the treatment of alcoholism and opioid addiction by combining cutting-edge medicine, behavioral science, and mobile technology."
About BioCorRx
BioCorRx Inc. (OTCMKTS:BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The company plans to seek FDA approval for BICX101 and/or its naltrexone implant product(s).
For more information on BICX, visit www.BioCorRx.com.
About DynamiCare Health
DynamiCare Health, Inc. is a Boston-based tech startup building a mobile platform to assist healthcare providers and patients with addiction recovery. DynamiCare Rewards™, the company's first product, is a set of tools for patients who want to focus and sustain their sobriety efforts by using state-of-the-art behavioral rewards. Based on the psychological model of operant conditioning, the use of incentives in addiction treatment, Contingency Management, is recommended by the U.S. Surgeon General, the American Society of Addiction Medicine, and the National Institutes of Health. The company was founded in May 2016 by David R. Gastfriend MD, a leading expert in addiction psychiatry, and his son Eric Gastfriend, former General Manager of the venture-backed cloud gaming startup Happy Cloud and a Harvard Business School MBA.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
BICX@crescendo-ir.com
212-671-1020 x304
Will see 17s&18s today
I had a buy order of 0.0006 this morning looool
Moving it up to 0.0013 now
BOOOOOOOMMMMMM!!!!
100% agree !! When it's time for the PPS to fly IT WILL FLY , No looking back :)
0.235 up AGIAN : )
http://ocularusa.com/index.php?newsid=46072
Drug overdose deaths overwhelm Maryland medical examiner’s office
Published: 17 apr 2017 ? 14:37, U.S.
The heroin epidemic is killing so many people in the state of Maryland that its medical examiner’s office is straining to keep up, which could threaten its accreditation. Autopsies in the state have grown 40 percent since 2010 – almost 100 more a year.
“Everyone continues to add on work hours and work faster and hopefully not take short cuts,” Dr. David R. Fowler, Maryland’s chief medical examiner, told the Baltimore Sun. “They absorb this extra load. But there is a point where they can’t continue to add to that and expect the system will function.”
580 new U.S. heroin users/day; 284% one year surge in Maryland #fentanyl deaths: https://t.co/qxdd9mmTqb$BICX$ALKS#opioidepidemic
— BioCorRx, Inc. (@BioCorRxInc) April 17, 2017
Medical examiner pathologists are accredited to carry out a set number of autopsies a year to ensure quality control and confidence in the results. The situation has implications for the criminal justice and public health systems, which rely on the autopsies in court cases.
“Maryland is currently fully accredited,” Peterson said. “But as is the case with many offices, it might be facing loss of that accreditation due to the intersection of caseload and staffing level.”
State pathologists are performing about 40 percent more autopsies than in 2010, almost 100 more per pathologist, and the toxicology lab runs nonstop, according to officials. There was no increase in examiners and the office struggles to hold on to support staff.
? STATE OF EMERGENCY ? declared by #Maryland Governor Hogan. Heroin/Opioid Epidemic. Deaths have doubled. pic.twitter.com/VgTS89GaIy
— EastCoastAlert ? (@Eastcoastphotog) March 2, 2017
The office handled 14,385 cases in fiscal year 2016 for deaths caused by injury, homicide, or suicide and those that were untimely, suspicious, or not attended by a physician. The office performed 5,439 autopsies.
Deaths from drug overdose in the state rose to 1,468 in the first nine months of 2016, up from 1,259 for all of 2015, and more than twice as many as 2010. Of those deaths, 900 were related to heroin, and more than 700 related to fentanyl – a more powerful opioid that is often mixed with heroin.
In the first quarter of fiscal 2017, the agency’s pathologists were on target to perform 328 autopsies, exceeding the limit of 325 for maintaining accreditation.
The challenge is not limited to Maryland.
The combination of additional and more complex cases is overwhelming medical examiners’ offices across the country, particularly along the East Coast, leaving many on the verge of losing accreditation.
AP reported that the Connecticut medical examiner’s office had considered renting a refrigerated truck to store extra corpses, because its storage area had neared capacity at times.
In Wisconsin, the Milwaukee County medical examiner’s office sometimes had to put bodies on Army style cots in its refrigerated storage because it was running out of gurneys.
Ohio limits doctors to prescribing #opioids to 7 days https://t.co/5QvGU2SZlhpic.twitter.com/OzFfPpn596
— RT America (@RT_America) March 30, 2017
The Hamilton County coroner’s office in Cincinnati had a 100-day backlog of DNA testing for police drug investigations, largely because of increased overdose deaths.
Fatal drug overdoses double from 15 yrs ago – gov't study https://t.co/fK3TMXna46pic.twitter.com/3q8bctYXzA
— RT America (@RT_America) December 22, 2016
A record 47,055 people died from drug overdose in the US in 2014, according to the latest figures from the federal Centers for Disease Control and Prevention. The number was up seven percent from 2013, spurred by increases in heroin and opioid painkiller deaths.